Web Watch

Share this article:
Television as an advertising medium is losing its edge. According to a recent McKinsey & Co. report, there are half as many viewers of primetime broadcast television as ithere were10 years ago. But despite this decline in viewership, television advertisers have actually increased their investment in the medium by almost 40% during the last decade. One wonders how long it will take before these advertisers tire of paying more money to reach fewer people.

Considering how teenagers consume media, it won't be long before television ad dollars shift to other media. Teens now spend half as much time watching television as their parents and spend 600% more time online.

Young adults (ages 18–26) already are online more than they watch television and tend to be early adopters of new technology, according to Forrester Research. People in this age group are also heavy users of electronic gadgets, and are more interested in blogs, podcasts and mobile web advertisements.

If marketing dollars follow eyeballs, the media mix over the next few years will include less broadcast television combined with more new media.

There's evidence that this is happening already. Big advertisers like J&J, Coca Cola, Proctor & Gamble and Chrysler have either decided not to participate in the network television upfront market or increased their online and wireless spending to extend the impact of their 30-second television spots.

The real challenge is to leverage what each medium does best and build a more intelligent media plan by integrating television, radio, Internet, wireless, print and even outdoor advertising.
If you're now experimenting to find out what works best, you're in good company. If you're still on the sidelines, it's time to get in the game.

Dan McKillen is president of the HealthDay news service

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...